AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6752962 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study 31483938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Multivariate Integrated Sound Therapy (T-MIST)
Number of subjects: 148
Study 31483938 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Inhibition Test (RIT)
Number of subjects: 148
Study 31483938 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiometric tinnitus loudness measures
Number of subjects: 148
Study 26990672 — intervention group
Group type: EXPERIMENTAL
Intervention: Written breastfeeding information in pregnancy and proactive breastfeeding‐focused support phone calls
Number of subjects: 459
Study 26990672 — intervention group
Group type: COMPARATOR
Intervention: General birth‐related information with proactive support calls
Number of subjects: 459
Study 26990672 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 459
Study 26990672 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 459
Study 26498242 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 5 mg
Number of subjects: 13
Study 26498242 — intervention group
Group type: COMPARATOR
Intervention: Rilmazafone 1 mg
Number of subjects: 13
Study 26498242 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.125 mg
Number of subjects: 13
Study 26498242 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 13
Study 24367931 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN or IFN‐α
Number of subjects: 0
Study 21864613 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1107
Number of subjects: 40
Study 21864613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active comparator (licensed Td vaccine)
Number of subjects: 40
Study 21864613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21864613 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1107 and Active comparator
Number of subjects: 40
Study 19118695 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light-filtering IOL (Hoya AF-1 YA-60BB)
Number of subjects: 24
Study 19118695 — intervention group
Group type: COMPARATOR
Intervention: UV-filtering IOL (Hoya AF-1 VA-60BB)
Number of subjects: 24
Study 19118695 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective visual impression
Number of subjects: 24
Study 17652807 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Number of subjects: 0
Study 17652807 — intervention group
Group type: COMPARATOR
Intervention: Anthracyclines
Number of subjects: 0
Study 15270155 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 240
Study 15270155 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education (control)
Number of subjects: 240
Study 11226783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Q‐switched Nd:YAG laser (ARC GmbH)
Number of subjects: 100
Study 9400950 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP/VNR (Cisplatin 100 mg m-2 on day 1 + Vinorelbine 25 mg m-2 i.v. on days 1 and 8 every 21 days for three cycles)
Number of subjects: 100
Study 9400950 — intervention group
Group type: COMPARATOR
Intervention: IFO/EPI (Ifosfamide 2.5 g m-2 with mesna on day 1 + High-dose Epirubicin 100 mg m-2 on day 1 every 21 days for three cycles)
Number of subjects: 100
Study 8423870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DGAVP treatment
Number of subjects: 32
Study 8423870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2881482 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy polysaccharide (10 g)
Number of subjects: 7
Study 31449303 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET) intervention group
Number of subjects: 55
Study 31449303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 31449303 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 55
Study 31449303 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including MET, control, and sham)
Number of subjects: 55
Study 29720719 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation
Number of subjects: 20
Study 29720719 — intervention group
Group type: COMPARATOR
Intervention: No surgical navigation (Control)
Number of subjects: 20
Study 26720428 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided MTP
Number of subjects: 111
Study 26720428 — intervention group
Group type: COMPARATOR
Intervention: CCA-guided MTP
Number of subjects: 111
Study 24093504 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (200/25 μg)
Number of subjects: 85
Study 24093504 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (800/100 μg)
Number of subjects: 85
Study 24093504 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 85
Study 23084328 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebos (inducing minor sensations)
Number of subjects: 144
Study 23084328 — intervention group
Group type: COMPARATOR
Intervention: Inert placebos (sesame oil)
Number of subjects: 144
Study 23084328 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebos (sesame oil with 0.014% capsaicin)
Number of subjects: 144
Study 23084328 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled clinical trials (50% chance)
Number of subjects: 144
Study 23084328 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor drug onset sensations
Number of subjects: 144
Study 20702117 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 18973991 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 546
Study 18973991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/day)
Number of subjects: 546
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydatid cyst fluid (HCF)
Number of subjects: 0
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: Native antigen B (AgB)
Number of subjects: 0
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: AgB8/1 subunit
Number of subjects: 0
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: AgB-derived synthetic peptide
Number of subjects: 0
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: AgB8/2 subunit
Number of subjects: 0
Study 15956395 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cytosolic malate dehydrogenase (EgMDH)
Number of subjects: 0
Study 12651273 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 57
Study 12651273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10565591 — intervention group
Group type: COMPARATOR
Intervention: Stiripentol (STP) in a placebo-controlled trial
Number of subjects: 212
Study 10565591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol (STP) in an open trial
Number of subjects: 212
Study 10565591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol (STP) long-term follow-up
Number of subjects: 212
Study 10565591 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in the study
Number of subjects: 212
Study 8907095 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 210
Study 8907095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral treatment
Number of subjects: 210
Study 8907095 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 210
Study 8907095 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact plus 2 mg of nicotine gum
Number of subjects: 210
Study 1863377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided biopsy
Number of subjects: 0
Study 1863377 — intervention group
Group type: COMPARATOR
Intervention: Freehand biopsy
Number of subjects: 0
Study 6136395 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R), 15‐methyl‐PGE2 (200 micrograms/day)
Number of subjects: 24
Study 6136395 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (2.0 g/day)
Number of subjects: 24
Study 30639089 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative bladder backfilling with 150 mL of normal saline
Number of subjects: 91
Study 30639089 — intervention group
Group type: COMPARATOR
Intervention: Control group (drained bladder)
Number of subjects: 91
Study 30106949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuniform sampling patterns using a single-pixel camera
Number of subjects: 0
Study 30106949 — intervention group
Group type: COMPARATOR
Intervention: Regular square patterns
Number of subjects: 0
Study 26156227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (2 ml Tissucol®; Duploject, Baxter AG) applied on surgical wound before closure
Number of subjects: 15
Study 26156227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue applied)
Number of subjects: 15
Study 24252218 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-possible-self mental imagery exercise (15 min writing + 5 min imagery)
Number of subjects: 40
Study 24252218 — intervention group
Group type: COMPARATOR
Intervention: Typical day writing and imagery (15 min writing + 5 min imagery)
Number of subjects: 40
Study 22578446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 610
Study 22578446 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 610
Study 22578446 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous treatment
Number of subjects: 610
Study 22578446 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610
Study 21126958 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 170
Study 21126958 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide
Number of subjects: 170
Study 18254225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of metabolic disorders and stimulation of endothelial NO‐synthetase
Number of subjects: 0
Study 18254225 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of metabolic disorders alone
Number of subjects: 0
Study 18254225 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 15974221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerana glass ceramic inserts
Number of subjects: 60
Study 15974221 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Quartz glass ceramic inserts
Number of subjects: 60
Study 15974221 — intervention group
Group type: COMPARATOR
Intervention: Control group (bulk-filled with Tetric Ceram without inserts)
Number of subjects: 60
Study 15974221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test groups and the control group
Number of subjects: 60
Study 12908891 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n 5)
Number of subjects: 13
Study 12908891 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ALNA intake (10 g/d, n 4)
Number of subjects: 13
Study 12908891 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased EPA+DHA intake (1.5 g/d, n 5)
Number of subjects: 13
Study 10229728 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 4 weeks
Number of subjects: 40
Study 10229728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 40
Study 8730519 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive behaviors
Number of subjects: 624
Study 8730519 — intervention group
Group type: EXPERIMENTAL
Intervention: Undermining behaviors
Number of subjects: 624
Study 8730519 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial supportive behaviors
Number of subjects: 624
Study 1875415 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 doxorubicin
Number of subjects: 411
Study 1875415 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/m2 bisantrene
Number of subjects: 411
Study 1875415 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg/m2 mitoxantrone
Number of subjects: 411
Study 6871069 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (1 mg)
Number of subjects: 10
Study 6871069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6871069 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 29382674 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Flexibility training (MemFlex)
Number of subjects: 0
Study 29382674 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation control condition
Number of subjects: 0
Study 26631059 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat group (received regular reminders and educational messages)
Number of subjects: 224
Study 26631059 — intervention group
Group type: COMPARATOR
Intervention: Control group (received conventional management)
Number of subjects: 224
Study 25582269 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS applied 5 days per week for 3 weeks to the left dorsolateral prefrontal cortex
Number of subjects: 175
Study 25582269 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS applied similarly
Number of subjects: 175
Study 23881662 — intervention group
Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 12256
Study 20407434 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-only PEG-ELS
Number of subjects: 116
Study 20407434 — intervention group
Group type: COMPARATOR
Intervention: PM/AM PEG-ELS
Number of subjects: 116
Study 18715665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-based antiviral therapies or treatment with polymerase inhibitors
Number of subjects: 0
Study 18715665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 0
Study 18715665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa and ribavirin
Number of subjects: 0
Study 18715665 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR)
Number of subjects: 0
Study 17508074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 55
Study 17508074 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide
Number of subjects: 55
Study 14669615 — intervention group
Group type: EXPERIMENTAL
Intervention: prestarium (2‐4 mg/day)
Number of subjects: 42
Study 14669615 — intervention group
Group type: COMPARATOR
Intervention: standard combined therapy
Number of subjects: 42
Study 11071181 — intervention group
Group type: EXPERIMENTAL
Intervention: suplatast tosilate (100 mg three times daily)
Number of subjects: 85
Study 11071181 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study 9011485 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (1.5 micrograms/kg daily)
Number of subjects: 67
Study 9011485 — intervention group
Group type: COMPARATOR
Intervention: Iodine (300 micrograms daily)
Number of subjects: 67
Study 1735253 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 600 micrograms twice daily
Number of subjects: 14
Study 6321684 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ) 320/1600 mg/day
Number of subjects: 61
Study 6321684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 6321684 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Number of subjects: 61
Study 30935731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoablation
Number of subjects: 20
Study 30935731 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 20
Study 30935731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30571234 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine aspirin 75 mg
Number of subjects: 100000
Study 30571234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Medicine Foundation screen-and-treat approach
Number of subjects: 100000
Study 30571234 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 100000
Study 26752495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine concentration 0.160 (EC50)
Number of subjects: 52
Study 26752495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine concentration 0.271 (EC90)
Number of subjects: 52
Study 26752495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine concentrations
Number of subjects: 52
Study 24102322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 85 mg/Naproxen sodium 500 mg (S/NS)
Number of subjects: 0
Study 24102322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22318095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg a day for 2 years
Number of subjects: 351
Study 22318095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 22318095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 351
Study 18606579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid urease test (RUT)
Number of subjects: 31
Study 18606579 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea breath test (UBT)
Number of subjects: 31
Study 17261965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoplus (n = 127 patients)
Number of subjects: 256
Study 17261965 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (n = 129 patients)
Number of subjects: 256
Study 15338072 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for calculating and drawing QoL-profiles
Number of subjects: 0
Study 11720459 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and best supportive care (BSC)
Number of subjects: 113
Study 11720459 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 113
Study 9848537 — intervention group
Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR) with polyglycolide/lactide bioabsorbable membrane
Number of subjects: 12
Study 9848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpedicle Connective Tissue Graft (SCTG)
Number of subjects: 12
Study 8083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (single 7-8 Gy fraction administered < 4 h before surgery)
Number of subjects: 122
Study 8083129 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation (single 7-8 Gy fraction administered < 48 h after surgery)
Number of subjects: 122
Study 2521644 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine 200 mg/day for 3 weeks
Number of subjects: 10
Study 2521644 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1147583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g every 6 h for 48 h
Number of subjects: 20
Study 1147583 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin 2 g every 6 h for 48 h
Number of subjects: 20
Study 30640799 — intervention group
Group type: EXPERIMENTAL
Intervention: In-simulation debriefing
Number of subjects: 0
Study 30640799 — intervention group
Group type: COMPARATOR
Intervention: Postsimulation debriefing
Number of subjects: 0
Study 28085888 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO-Ci dialysis
Number of subjects: 48
Study 28085888 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 48
Study 25855898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 650
Study 25855898 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal siRNA
Number of subjects: 650
Study 25855898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Angiopoietin-2 siRNA
Number of subjects: 650
Study 25855898 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors)
Number of subjects: 650
Study 25855898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study 23977178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet + education intervention
Number of subjects: 317
Study 23977178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet only intervention
Number of subjects: 317
Study 23977178 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet (with or without education)
Number of subjects: 317
Study 23977178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet with education
Number of subjects: 317
Study 23977178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet without education
Number of subjects: 317
Study 21819723 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified thoracoscopic oesophagectomy
Number of subjects: 2
Study 21819723 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive oesophagectomy
Number of subjects: 2
Study 19516120 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1015
Study 19516120 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1015
Study 19516120 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with AMD and large hemorrhagic lesions (>3.5 MPS disk areas)
Number of subjects: 1015
Study 19516120 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with AMD and larger hemorrhagic lesions (>16 MPS disk areas) and poor visual acuity (best-corrected visual acuity <=20/1280)
Number of subjects: 1015
Study 16463197 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFC
Number of subjects: 95
Study 16463197 — intervention group
Group type: COMPARATOR
Intervention: CP
Number of subjects: 95
Study 15174779 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of elemental zinc daily)
Number of subjects: 115
Study 15174779 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplement without zinc)
Number of subjects: 115
Study 11394683 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent goal structure
Number of subjects: 0
Study 11394683 — intervention group
Group type: COMPARATOR
Intervention: Varied goal structures
Number of subjects: 0
Study 11394683 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent spatial arrangement of notes
Number of subjects: 0
Study 11394683 — intervention group
Group type: COMPARATOR
Intervention: Varied locations of notes
Number of subjects: 0
Study 9736819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltrate samples from hemodialysis sessions
Number of subjects: 6